CINECA IRIS Institutional Research Information System

SCHIRRIPA, MARTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.932
AS - Asia 1.433
EU - Europa 957
SA - Sud America 307
Continente sconosciuto - Info sul continente non disponibili 118
AF - Africa 89
OC - Oceania 2
Totale 6.838
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.793
SG - Singapore 496
CN - Cina 357
IT - Italia 264
BR - Brasile 245
HK - Hong Kong 221
VN - Vietnam 169
DE - Germania 115
SE - Svezia 110
CA - Canada 90
GB - Regno Unito 86
FR - Francia 82
BG - Bulgaria 79
RU - Federazione Russa 57
AT - Austria 42
IN - India 38
TR - Turchia 33
AR - Argentina 27
FI - Finlandia 24
CI - Costa d'Avorio 23
NL - Olanda 21
NG - Nigeria 20
BD - Bangladesh 18
JP - Giappone 18
SN - Senegal 17
MX - Messico 15
EC - Ecuador 13
ID - Indonesia 12
UA - Ucraina 12
PL - Polonia 11
PK - Pakistan 10
SA - Arabia Saudita 9
IQ - Iraq 8
ZA - Sudafrica 8
CZ - Repubblica Ceca 7
ES - Italia 7
KR - Corea 7
LT - Lituania 7
VE - Venezuela 7
AL - Albania 6
CR - Costa Rica 6
EE - Estonia 6
PE - Perù 5
TW - Taiwan 5
UZ - Uzbekistan 5
BE - Belgio 4
CH - Svizzera 4
CO - Colombia 4
EG - Egitto 4
JM - Giamaica 4
MA - Marocco 4
PA - Panama 4
CL - Cile 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
GT - Guatemala 3
IL - Israele 3
PH - Filippine 3
SV - El Salvador 3
TN - Tunisia 3
TT - Trinidad e Tobago 3
AE - Emirati Arabi Uniti 2
BH - Bahrain 2
BJ - Benin 2
IE - Irlanda 2
KE - Kenya 2
KZ - Kazakistan 2
MY - Malesia 2
NI - Nicaragua 2
NP - Nepal 2
OM - Oman 2
PR - Porto Rico 2
PY - Paraguay 2
RO - Romania 2
AU - Australia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BW - Botswana 1
CW - ???statistics.table.value.countryCode.CW??? 1
DK - Danimarca 1
ET - Etiopia 1
GD - Grenada 1
HR - Croazia 1
HU - Ungheria 1
IM - Isola di Man 1
IR - Iran 1
IS - Islanda 1
KG - Kirghizistan 1
KH - Cambogia 1
LK - Sri Lanka 1
MM - Myanmar 1
MQ - Martinica 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
QA - Qatar 1
RE - Reunion 1
RS - Serbia 1
SI - Slovenia 1
TH - Thailandia 1
Totale 6.718
Salva come PNG Salva come JPEG
Città #
Ashburn 437
Singapore 275
Woodbridge 271
Fairfield 222
Hong Kong 215
Santa Clara 204
San Jose 178
Houston 166
Chandler 115
Seattle 111
Dallas 98
Council Bluffs 88
Cambridge 86
Shanghai 86
Ann Arbor 80
Sofia 79
New York 77
Beijing 73
Wilmington 72
Boardman 47
Princeton 44
Ho Chi Minh City 43
Los Angeles 42
São Paulo 38
Vienna 38
Lauterbourg 35
Hanoi 34
Lawrence 31
Ottawa 29
Des Moines 27
Florence 27
Abidjan 23
Medford 23
London 21
Milan 21
Bremen 20
Lagos 20
Istanbul 19
Colorado Springs 18
Buffalo 17
Dakar 17
Düsseldorf 17
Atlanta 16
Dearborn 16
Lancaster 16
Montreal 16
Redondo Beach 16
Tokyo 15
North Bergen 14
Serra 14
Munich 13
Nanjing 13
San Diego 13
Denver 11
Frankfurt am Main 11
Pisa 11
Toronto 11
Warsaw 11
Phoenix 10
Rio de Janeiro 10
Chicago 9
Curitiba 9
Marseille 9
Nuremberg 9
Orem 9
Baltimore 8
Brasília 8
Brooklyn 8
Dong Ket 8
Memphis 8
Redwood City 8
Rome 8
Da Nang 7
Mexico City 7
Shenyang 7
Turku 7
Baghdad 6
Boston 6
Bắc Ninh 6
Chennai 6
Johannesburg 6
Kunming 6
Positano 6
Quito 6
Seacroft 6
Ankara 5
Detroit 5
New Delhi 5
Ogden 5
Thái Nguyên 5
Tirana 5
Brussels 4
Carrara 4
Changsha 4
Charlotte 4
Fuzhou 4
Guangzhou 4
Haiphong 4
Hangzhou 4
Hebei 4
Totale 4.070
Salva come PNG Salva come JPEG
Nome #
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 306
TRIBE-2: A phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group 233
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients 224
TAS-102 for the treatment of metastatic colorectal cancer 202
Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial 201
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: Final results of the randomized BEBYP trial 189
Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO 188
NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients 186
Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib 186
Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials 183
Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: A clinical and molecular proof of concept study 179
Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: Data from FIRE-3 and TRIBE trials 177
Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer 177
Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib 173
KRAS status and risk of venous thromboembolic events in patients with metastatic colorectal cancer: a case-control study. 169
Durvalumab in Advanced Biliary Tract Cancer: Real‐World Data From a Large Cohort of Patients Across Multiple International Centers 167
Oral multikinase inhibitor regorafenib for the treatment of patients with metastatic colorectal cancer 161
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 160
Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer 157
Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer 157
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 153
Clinical significance of tlr1 i602s polymorphism for patients with metastatic colorectal cancer treated with folfiri plus bevacizumab 149
Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study 142
BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection 139
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data 138
Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial 133
Phase II study of single-agent cetuximab in KRAS g13d mutant metastatic colorectal cancer 132
Circulating microRNAs in metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib 132
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 130
null 129
Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial 127
Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study 123
Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR Study 121
The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer 118
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer 110
DPYD c.1905+1G>A and c.2846 A>T and UGT1A1*28 allelic variants as predictors of toxicity: Pharmacogenetic translational analysis from the phase III TRIBE study in metastatic colorectal cancer. 104
Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients 103
null 98
First-line chemotherapy for mCRC-a review and evidence-based algorithm 95
null 85
Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer 79
Impact of Antibiotic Therapy in Patients with Cholangiocarcinoma Treated with Chemoimmunotherapy 72
null 65
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab 64
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population 63
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 58
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer 58
Reply: Comment on 'Histopathologic evaluation of liver metastases from colorectal cancer patients treated with FOLFOXIRI plus bevacizumab' 49
null 48
Effectiveness of FTD/TPI plus bevacizumab and impact of prior bevacizumab exposure in patients with mCRC: the Italian FLOWER study 46
Totale 6.838
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.894
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.894
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022281 0 0 0 7 57 54 9 7 16 26 10 95
2022/2023439 40 66 31 56 47 55 4 20 84 4 31 1
2023/2024241 19 16 37 4 42 37 24 6 4 2 21 29
2024/20251.236 5 61 71 44 160 169 81 46 105 175 102 217
2025/20261.903 108 197 173 208 173 161 278 126 133 205 88 53
2026/20271.154 74 504 229 347 0 0 0 0 0 0 0 0
Totale 6.838